Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (381-390 of 493) with videos related to

Pageof 50
Sort By:
Molecular Cancer Research : MCR|May 29, 2012
State of the science: an update on renal cell carcinomaEric Jonasch, P Andrew Futreal, Ian J Davis, et al.
Journal for Immunotherapy of Cancer|April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.
European Urology Oncology|July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 TrialBrian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinomaT K Choueiri, A P Fay, K P Gray, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.
Pageof 50

Showing results (381-390 of 493) with videos related to

Sort By:
Pageof 50
Molecular Cancer Research : MCR|May 29, 2012
State of the science: an update on renal cell carcinomaEric Jonasch, P Andrew Futreal, Ian J Davis, et al.
Journal for Immunotherapy of Cancer|April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.
European Urology Oncology|July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 TrialBrian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinomaT K Choueiri, A P Fay, K P Gray, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.
Pageof 50